Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-930-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$712.97 million
Profitability
Miscellaneous
Employees1,800
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) issued its quarterly earnings data on Thursday, August, 1st. The medical device company reported $0.41 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.41. The medical device company earned $150.55 million during the quarter, compared to analyst estimates of $184.93 million. Globus Medical had a return on equity of 13.29% and a net margin of 19.30%. The business's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.44 EPS. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical updated its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of $1.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.72. The company issued revenue guidance of $770-775 million, compared to the consensus revenue estimate of $768.63 million.
What price target have analysts set for GMED?
9 brokerages have issued 1 year target prices for Globus Medical's shares. Their predictions range from $45.00 to $65.00. On average, they anticipate Globus Medical's stock price to reach $56.67 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price. View Analyst Price Targets for Globus Medical.
What is the consensus analysts' recommendation for Globus Medical?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical posted a mixed second-quarter performance with earnings meeting the Zacks Consensus Estimate while revenues beating the mark. Globus Medical witnessed strength in the United States and the international regions as well as in the Musculoskeletal solutions and Enabling Technologies segments. The company has delivered strong top-line numbers for its Spine arm. Implant pull-through from ExcelsiusGPS placements and back-to-back record sales force recruiting years were the primary growth drivers. Overall, the stock has outperformed its industry in the past three months. However, the pricing scenario is persistently tough for Globus Medical." (8/6/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019)
Has Globus Medical been receiving favorable news coverage?
Headlines about GMED stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Globus Medical earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Globus Medical.
Are investors shorting Globus Medical?
Globus Medical saw a decline in short interest in September. As of September 15th, there was short interest totalling 2,200,000 shares, a decline of 23.1% from the August 15th total of 2,860,000 shares. Based on an average daily volume of 591,600 shares, the short-interest ratio is currently 3.7 days. Approximately 2.9% of the company's shares are sold short. View Globus Medical's Current Options Chain.
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD) and Nevro (NVRO).
What other stocks do shareholders of Globus Medical own?
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
- Mr. David M. Demski, CEO & Director (Age 61)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
- Mr. David D. Davidar, Co-Founder & Director (Age 53)
- Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sterling Investment Advisors Ltd. (0.28%), Gofen & Glossberg LLC IL (0.07%), Pacer Advisors Inc. (0.03%), Assenagon Asset Management S.A. (0.02%), State of Alaska Department of Revenue (0.01%) and CIBC Private Wealth Group LLC (0.01%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which major investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including Sterling Investment Advisors Ltd., Pacer Advisors Inc., CIBC Private Wealth Group LLC and Gofen & Glossberg LLC IL. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical.
Which major investors are buying Globus Medical stock?
GMED stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Assenagon Asset Management S.A., Toth Financial Advisory Corp, Nisa Investment Advisors LLC, Fox Run Management L.L.C. and Meeder Asset Management Inc.. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $51.01.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $5.06 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical.
What is Globus Medical's official website?
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (NYSE GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
